Pricing Log in Create free account

ALX Oncology Holdings Inc. (ALXO) vs Zentalis Pharmaceuticals, Inc. (ZNTL)

ALX Oncology Holdings Inc. and Zentalis Pharmaceuticals, Inc. are both Biotechnology companies. ALX Oncology Holdings Inc. and Zentalis Pharmaceuticals, Inc. are of similar size ($162.8M and $159.7M). Across the 10 metrics below, ALX Oncology Holdings Inc. leads on 5 and Zentalis Pharmaceuticals, Inc. on 5.

Valuation

Metric ALXO ZNTL Biotechnology median
P/E n/m n/m 10.60
P/S 64.54 n/m 9.40
P/B 1.16 0.85 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.34 0.66
EV/Sales 13.96 n/m 9.02
Earnings yield (97.41%) (113.37%) (32.88%)
Free cash flow yield (45.06%) (104.34%) (23.13%)

Profitability

Metric ALXO ZNTL Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (80.65%) (66.75%) (51.96%)
Return on assets (63.16%) (49.22%) (46.06%)
Return on invested capital (673.30%) 0.00% 0.00%

Growth

Metric ALXO ZNTL Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 26.36% 18.03% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALXO ZNTL Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 9.71 4.82 4.97
Net debt to EBITDA 0.34 1.59 1.01

Dividend

Metric ALXO ZNTL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALXO ZNTL Biotechnology median
Market cap 159.71m 162.84m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack